Even when peptides become eligible for compounding, they have not gone through the clinical trial process required for FDA drug approval
For women specifically, the way the growth hormone axis shifts after 35 changes the conversation, which our team covers in detail in our guide to why the growth hormone axis changes for women after 35 and how a supervised CJC-1295/Ipamorelin protocol addresses it
Studies have also examined GHK-Cu, TB-500, BPC-157, and KPV in contexts involving inflammatory signaling pathways and barrier integrity models
Quick Comparison: GH Secretagogues and Related Compounds Quick Comparison: GH Secretagogues and Related Compounds GHRH Analogs: CJC-1295, Sermorelin, and Tesamorelin GHRH analogs mimic the natural hypothalamic signal that stimulates the pituitary gland to release growth hormone
Always follow a providers guidance when combining peptides